M&T Bank Corp Buys 48,381 Shares of Certara, Inc. (NASDAQ:CERT)

M&T Bank Corp raised its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 41.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 163,933 shares of the company's stock after purchasing an additional 48,381 shares during the period. M&T Bank Corp owned 0.10% of Certara worth $1,746,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Atria Investments Inc raised its stake in Certara by 21.6% during the 3rd quarter. Atria Investments Inc now owns 19,743 shares of the company's stock worth $231,000 after acquiring an additional 3,501 shares during the period. TimesSquare Capital Management LLC raised its position in shares of Certara by 3.1% during the 3rd quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company's stock valued at $11,202,000 after purchasing an additional 29,090 shares during the period. Versor Investments LP purchased a new position in shares of Certara during the 3rd quarter valued at $162,000. Geneva Capital Management LLC boosted its holdings in Certara by 0.7% in the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company's stock worth $64,525,000 after buying an additional 37,392 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its stake in Certara by 6.8% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 211,224 shares of the company's stock worth $2,473,000 after buying an additional 13,500 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on CERT shares. TD Cowen assumed coverage on Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective for the company. Stephens restated an "overweight" rating and issued a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Barclays boosted their target price on shares of Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Finally, William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $15.83.

Remove Ads

Certara Price Performance

Shares of NASDAQ CERT traded down $0.58 during midday trading on Thursday, reaching $10.43. 1,092,624 shares of the stock traded hands, compared to its average volume of 990,795. The company's 50 day moving average is $12.59 and its 200 day moving average is $11.57. Certara, Inc. has a one year low of $9.41 and a one year high of $19.29. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock has a market capitalization of $1.68 billion, a PE ratio of -52.15, a P/E/G ratio of 9.29 and a beta of 1.60.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.